These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 18350599)

  • 1. Is human hepatocellular carcinoma a hormone-responsive tumor?
    Di Maio M; Daniele B; Pignata S; Gallo C; De Maio E; Morabito A; Piccirillo MC; Perrone F
    World J Gastroenterol; 2008 Mar; 14(11):1682-9. PubMed ID: 18350599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormonal treatment of human hepatocellular carcinoma.
    Di Maio M; De Maio E; Morabito A; D'Aniello R; De Feo G; Gallo C; Perrone F
    Ann N Y Acad Sci; 2006 Nov; 1089():252-61. PubMed ID: 17261772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine treatment of hepatocellular carcinoma. Any evidence of benefit?
    Pignata S; Daniele B; Gallo C; De Vivo R; Monfardini S; Perrone F
    Eur J Cancer; 1998 Jan; 34(1):25-32. PubMed ID: 9624234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated expression of Erbin destabilizes ERĪ± protein and promotes tumorigenesis in hepatocellular carcinoma.
    Wu H; Yao S; Zhang S; Wang JR; Guo PD; Li XM; Gan WJ; Mei L; Gao TM; Li JM
    J Hepatol; 2017 Jun; 66(6):1193-1204. PubMed ID: 28192186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
    Howell SJ; Johnston SR; Howell A
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of tamoxifen in hepatocellular carcinoma: a review and paradigm shift.
    Tan CK; Chow PK; Findlay M; Wong C; Machin D
    J Gastroenterol Hepatol; 2000 Jul; 15(7):725-9. PubMed ID: 10937676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type of estrogen receptor determines response to antiestrogen therapy.
    Villa E; Dugani A; Fantoni E; Camellini L; Buttafoco P; Grottola A; Pompei G; De Santis M; Ferrari A; Manenti F
    Cancer Res; 1996 Sep; 56(17):3883-5. PubMed ID: 8752151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study.
    Liu CL; Fan ST; Ng IO; Lo CM; Poon RT; Wong J
    Am J Gastroenterol; 2000 Jan; 95(1):218-22. PubMed ID: 10638587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M; Kodama T
    In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen for hepatocellular carcinoma.
    Nowak A; Findlay M; Culjak G; Stockler M
    Cochrane Database Syst Rev; 2004; (3):CD001024. PubMed ID: 15266436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Third generation aromatase inhibitors in metastatic breast cancer patients failing tamoxifen. Randomized comparisons with megestrol acetate: a critical review.
    Bonte J
    Eur J Gynaecol Oncol; 2000; 21(6):555-9. PubMed ID: 11214609
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systematic review.
    Nowak AK; Stockler MR; Chow PK; Findlay M
    Cancer; 2005 Apr; 103(7):1408-14. PubMed ID: 15744746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of randomized trials of systemic adjuvant therapy.
    Ravdin PM
    Cancer Treat Res; 2000; 103():157-81. PubMed ID: 10948446
    [No Abstract]   [Full Text] [Related]  

  • 14. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors.
    Villa E; Ferretti I; Grottola A; Buttafoco P; Buono MG; Giannini F; Manno M; Bertani H; Dugani A; Manenti F
    Br J Cancer; 2001 Apr; 84(7):881-5. PubMed ID: 11286465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study of estrogen receptors in hepatocellular carcinoma and its response to anti-estrogen therapy].
    Zheng T; Zhang Q; Xie Z
    Zhonghua Zhong Liu Za Zhi; 1997 Nov; 19(6):451-3. PubMed ID: 10920881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma.
    Schwartz JD; Beutler AS
    Anticancer Drugs; 2004 Jun; 15(5):439-52. PubMed ID: 15166617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen in hepatocellular carcinoma.
    Chow P; Kiat TC; Choo TB; Machin D
    Lancet; 1998 Sep; 352(9130):819-20. PubMed ID: 9737316
    [No Abstract]   [Full Text] [Related]  

  • 18. Chemotherapy and medical treatment of hepatocellular carcinoma (HCC).
    Rougier P; Mitry E; Clavero-Fabri MC
    Hepatogastroenterology; 1998 Aug; 45 Suppl 3():1264-6. PubMed ID: 9730386
    [No Abstract]   [Full Text] [Related]  

  • 19. [Does anti-estrogen therapy after estrogen receptor analysis have value in palliative therapy of hepatocellular carcinoma?].
    Kreysel C; Porschen R
    Z Gastroenterol; 1998 Jul; 36(7):605-7. PubMed ID: 9738309
    [No Abstract]   [Full Text] [Related]  

  • 20. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
    Van Poznak CH; Hayes DF
    J Natl Cancer Inst; 2006 Sep; 98(18):1261-3. PubMed ID: 16985239
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.